Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Faces Amendment Gauntlet As User Fee Passage Nears

This article was originally published in The Pink Sheet Daily

Executive Summary

Seventeen amendments will be considered and final passage could come May 24. Along with a ban on generic drug settlements is a proposal to allow members of Congress to observe FDA-industry user fee negotiations.

You may also be interested in...



Califf Nomination Hearing Expected Before Holiday Season

The Senate HELP Committee has competing priorities, but the FDA commissioner nominee still seems to have smooth path to confirmation.

Califf Nomination Hearing Expected Before Holiday Season

The Senate HELP Committee has competing priorities, but the FDA commissioner nominee still seems to have smooth path to confirmation.

Califf Nomination Hearing Expected Before Holiday Season

Senate HELP Committee has competing priorities, but FDA commissioner nominee still seems to have smooth path to confirmation.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS074162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel